Neurocrine Biosciences, Inc (NBIX) Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc (NASDAQ: NBIX) FY 2026 Other Release